30 September, 2017 SOURCE Amgen THOUSAND OAKS, Calif. and BRUSSELS, Sept. 11, 2017 /PRNewswire/ — Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced detailed results from the Phase 3...
Written by:Sergio Franco
30 September, 2017 / Comments Off on Evenity (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine
31 August, 2017
19 March, 2018
6 April, 2017
28 March, 2020
18 May, 2026
6 April, 2026
26 February, 2026
Written by:
